XML 112 R97.htm IDEA: XBRL DOCUMENT v3.8.0.1
Selected Quarterly Financial Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2017
 [1]
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2016
 [2]
Sep. 30, 2016
 [2]
Jun. 30, 2016
 [2]
Mar. 31, 2016
 [2]
Dec. 31, 2015
Sep. 30, 2015
Jun. 30, 2015
Mar. 31, 2015
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Selected Quarterly Financial Information [Abstract]                              
REVENUE $ 52,826 $ 43,999 $ 47,818 $ 45,059 $ 45,029 $ 45,252 $ 47,083 $ 43,016 $ 39,838 $ 36,703 $ 35,526 $ 33,831 $ 189,702 $ 180,380 $ 145,898
GROSS MARGIN 36,363 29,862 32,905 29,512 31,195 29,782 30,301 27,621 26,516 22,982 21,554 19,667 128,642 118,899 90,719
NET INCOME (LOSS) $ (3,007) $ 1,325 $ 3,163 $ 2,223 $ 2,897 $ 2,993 $ 2,347 $ 2,541 $ 2,636 $ 2,145 $ (502) $ (274) $ 3,704 $ 10,778 $ 4,005
INCOME (LOSS) PER COMMON SHARE - DILUTED $ (0.09) $ 0.04 $ 0.09 $ 0.06 $ 0.09 $ 0.09 $ 0.07 $ 0.08 $ 0.09 $ 0.07 $ (0.02) $ (0.01) $ 0.11 [3] $ 0.32 [3] $ 0.14 [3]
Gain on sale of Medafor investment                             $ 891
[1] In December 2017 we completed our acquisition of JOTEC, which is also being operated as a wholly owned subsidiary of CryoLife.
[2] In January 2016 we completed our acquisition of On-X Life Technologies Holdings, Inc., which is being operated as a wholly owned subsidiary of CryoLife. In 2016 we also sold our HeRO Graft product line and our ProCol product line, and ceased sales of these products during 2016.
[3] We excluded stock options from the calculation of diluted weighted-average common shares outstanding if the per share value, including the sum of (i) the exercise price of the options and (ii) the amount of the compensation cost attributed to future services and not yet recognized, was greater than the average market price of the shares, because the inclusion of these stock options would be antidilutive to income per common share. Accordingly, stock options to purchase 227,000, 1,000, and 710,000 shares for the years ended December 31, 2017, 2016, and 2015, respectively, were excluded from the calculation of diluted weighted-average common shares outstanding.